Outpatient intravenous treatment for infective endocarditis: Safety, effectiveness and one-year outcomes

Journal of Infection

Volumn 59, Issue 6, 2009, Pages 387-393

  Amodeo, Matthew R ^a,b   Clulow, Tamlin ^b   Lainchbury, John ^b   Murdoch, David R ^a,c   Gallagher, Kate ^b   Dyer, Amanda ^b   Metcalf, Sarah L ^b   Pithie, Alan D ^b   Chambers, Stephen T ^b,c  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Ambulatory care; Endocarditis; Home infusion therapy; Mortality; Treatment outcome

Indexed keywords

AMOXICILLIN; CEFAZOLIN; CEFTRIAXONE; ERTAPENEM; FLUCLOXACILLIN; GENTAMICIN; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTERIAL ENDOCARDITIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG SELF ADMINISTRATION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; FEMALE; FOLLOW UP; GEMELLA HAEMOLYSANS; HOSPITAL READMISSION; HUMAN; INFUSION SYSTEM; INTRAVENOUS ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW ZEALAND; OTOTOXICITY; OUTPATIENT CARE; PROGNOSIS; RECURRENT INFECTION; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS BOVIS; STREPTOCOCCUS INTERMEDIUS; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS VIRIDANS INFECTION; TOXIC HEPATITIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEW ZEALAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71549163474     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.09.009     Document Type: Article

References (30)

1. Sexton D.J., Tenenbaum M.J., Wilson W.R., Steckelberg J.M., Tice A.D., Gilbert D., et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 27 6 (1998) 1470-1474
2. Francioli P., Ruch W., and Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 21 6 (1995) 1406-1410
3. Stamboulian D., Bonvehi P., Arevalo C., Bologna R., Cassetti I., Scilingo V., et al. Antimicrobial management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis 13 Suppl. 2 (1991) S160-S163
4. Tice A.D., Rehm S.J., Dalovisio J.R., Bradley J.S., Martinelli L.P., Graham D.R., et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 38 12 (2004) 1651-1672
5. Andrews M.M., and von Reyn C.F. Patient selection criteria and management guidelines for outpatient parenteral antimicrobial therapy for native valve infective endocarditis. Clin Infect Dis 33 2 (2001) 203-209
6. Monteiro C.A., and Cobbs C.G. Outpatient Management of Infective Endocarditis. Curr Infect Dis Rep 3 4 (2001) 319-327
7. McMahon J.H., and O'Keeffe J.M. Victorian HITH Outcomes Study Group, Lindsay GM. Is hospital-in-the-home (HITH) treatment of bacterial endocarditis safe and effective?. Scand J Infect Dis 40 1 (2008) 40-43
8. Lopardo G. Management of endocarditis: outpatient parenteral antimicrobial treatment in Argentina. Chemotherapy 47 Suppl. 1 (2001) 24-32
9. Dimayuga E., and Brown R.B. Outpatient parenteral antimicrobial therapy for infective endocarditis. Infect Dis Clin Pract 4 (1995) 468-471
10. Huminer D., Bishara J., and Pitlik S. Home intravenous antimicrobial therapy for patients with infective endocarditis. Eur J Clin Microbiol Infect Dis 18 5 (1999 May) 330-334
11. Hughes D.W., Frei C.R., Maxwell P.R., Green K., Patterson J.E., Crawford G.E., et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 53 5 (2009) 2014-2019
12. Leder K., Turnidge J.D., Korman T.M., and Grayson M.L. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 43 1 (1999) 113-118
13. Baddour L.M., Wilson W.R., Bayer A.S., Fowler Jr. V.G., Bolger A.F., Levison M.E., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 111 23 (2005) e394-e434
14. Li J.S., Sexton D.J., Mick N., Nettles R., Fowler Jr. V.G., Ryan T., et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30 4 (2000) 633-638
15. Fowler Jr. V.G., Miro J.M., Hoen B., Cabell C.H., Abrutyn E., Rubinstein E., et al. ICE Investigators. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293 24 (2005) 3012-3021
16. Campbell S.E., Campbell M.K., Grimshaw J.M., and Walker A.E. A systematic review of discharge coding accuracy. J Public Health Med 23 3 (2001) 205-211
17. Murdoch D.R., Corey G.R., Hoen B., Miró J.M., Fowler Jr. V.G., Bayer A.S., et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169 5 (2009) 463-473
18. Miro J.M., Anguera I., Cabell C.H., Chen A.Y., Stafford J.A., Corey G.R., et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 41 4 (2005) 507-514
19. Cabell C.H., Jollis J.G., Peterson G.E., Corey G.R., Anderson D.J., Sexton D.J., et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 162 1 (2002) 90-94
20. Huggan P.J., Murdoch D.R., Gallagher K., and Chambers S.T. Concomitant Staphylococcus aureus bacteriuria is associated with poor clinical outcome in adults with S. aureus bacteraemia. J Hosp Infect 69 4 (2008) 345-349
21. Hill P.C., Birch M., Chambers S., Drinkovic D., Ellis-Pegler R.B., Everts R., et al. Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J 31 2 (2001) 97-103
22. Dworkin R.J., Lee B.L., Sande M.A., and Chambers H.F. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 2 8671 (1989) 1071-1073
23. Heldman A.W., Hartert T.V., Ray S.C., Daoud E.G., Kowalski T.E., Pompili V.J., et al. Oral antimicrobial treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 101 1 (1996) 68-76
24. Wynn M., Dalovisio J.R., Tice A.D., and Jiang X. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. Southampt Med J 98 6 (2005) 590-595
25. Upton A., Ellis-Pegler R.B., and Woodhouse A. Outpatient Parenteral Antimicrobial Therapy (OPAT): a review of experience at Auckland Hospital. N Z Med J 117 1200 (2004) U1020
26. Tornos M.P., Permanyer-Miralda G., Olona M., Gil M., Galve E., Almirante B., et al. Long-term complications of native valve infective endocarditis in non-addicts. A 15-year follow-up study. Ann Intern Med 117 7 (1992) 567-572
27. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin Infect Dis 27 1 (1998) 10-22
28. Chambers S., Gallagher K., Metcalf S., and Pithie A. Home intravenous antimicrobial service-twelve months experience in Christchurch. N Z Med J 115 1153 (2002) 216-218
29. Vella-Brincat J.W., Begg E.J., Kirkpatrick C.M., Zhang M., Chambers S.T., and Gallagher K. Protein binding of cefazolin is saturable in vivo both between and within patients. Br J Clin Pharmacol 63 (2007) 753-757
30. Nannini E.C., Singh K.V., and Murray B.E. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis 37 9 (2003) 1194-1198